

Lopinavir/ritonavir/umifenovir

S

Nausea, vomiting and diarrhoea following off-label treatment: case report

A 51-year-old man developed nausea, vomiting and diarrhoea following off-label treatment with umifenovir and lopinavir/ritonavir for COVID-19.

The man developed chest pain, fatigue, chest tightness and conscious fever. On 27 April 2020, he was admitted to a hospital in China. Based on investigational findings, he was diagnosed with COVID-19. He was started on oxygen therapy. He started receiving off-label treatment with oral umifenovir [arbidol] and oral lopinavir/ritonavir [lopinavir-ritonavir; *dosages not stated*]. Subsequently, he developed severe nausea, diarrhoea and vomiting secondary to umifenovir and lopinavir/ritonavir therapy [*time to reactions onsets not clearly stated*].

Umifenovir and lopinavir/ritonavir therapy was discontinued. On 28 April 2020, the man started receiving off-label treatment with SC injection of unspecified thymosin 1.6mg twice a week. He was discharged after total 15 days of hospitalisation. At 1 month follow-up, he reported no discomfort and his condition had improved.

Zheng QN, et al. Thymosin as a Possible Therapeutic Drug for Covid-19: A Case Report. World Journal of Clinical Cases 9: 4090-4094, No. 16, 6 Jun 2021. Available from:
URL: <http://doi.org/10.12998/wjcc.v9.i16.4090>

803582150